cmi_logo.png
[Latest] Global Cancer Cachexia Market Size/Share Worth USD 5.1 Billion by 2033 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 03, 2024 04:30 ET | Custom Market Insights
Austin, TX, USA, May 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cachexia Market Size, Trends and Insights By Therapeutics (Progestogen,...
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET | Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
cmi_logo.png
[Latest] Global Lipid Nanoparticles Market Size/Share Worth USD 1,899.8 Million by 2033 at a 14.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 02, 2024 04:30 ET | Custom Market Insights
Austin, TX< USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lipid Nanoparticles Market Size, Trends and Insights By Type (Nano-Structured...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
April 30, 2024 10:00 ET | RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
harnesstx-logo.png
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
April 24, 2024 03:00 ET | Harness Therapeutics
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...
Picture3.jpg
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024 07:49 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery...
cmi_logo.png
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 08, 2024 13:30 ET | Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 03, 2024 06:30 ET | Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
MetasTx-Logo_HoRes.jpg
MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry
March 25, 2024 07:48 ET | MetasTx LLC
Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.
CMP4_21_logo_full+color.jpg
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
March 21, 2024 07:58 ET | CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D